Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nafarelin
Drug ID BADD_D01513
Description Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Indications and Usage For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.
Marketing Status Prescription
ATC Code H01CA02
DrugBank ID DB00666
KEGG ID D08241
MeSH ID D017274
PubChem ID 25077405
TTD Drug ID D08WYM
NDC Product Code Not Available
Synonyms Nafarelin | Synarel | RS-94991-298 | RS 94991 298 | RS94991298 | Nafarelin Acetate | Nafarelin Acetate, Hydrate | Nafarelin Monoacetate
Chemical Information
Molecular Formula C66H83N17O13
CAS Registry Number 76932-56-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C 2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=C N7)NC(=O)C8CCC(=O)N8
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Nervousness19.06.02.003--Not Available
Neurosis19.06.01.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oestrogen deficiency21.11.02.003; 05.05.04.003--Not Available
Oliguria20.01.03.004--Not Available
Ophthalmoplegia17.17.02.005; 06.05.02.003--Not Available
Ovarian hyperstimulation syndrome05.05.01.013; 21.11.02.0070.045086%Not Available
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.0120.003921%
Pituitary infarction24.04.06.016; 18.02.02.004; 17.08.01.027; 05.03.04.006--Not Available
Pleural effusion22.05.02.0020.005881%
Pruritus23.03.12.001--
Puberty26.03.01.003--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.006--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rhinitis11.01.13.004; 22.07.03.006--
Seborrhoeic dermatitis23.03.04.018--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin odour abnormal23.03.03.012--
Tension19.06.02.005--Not Available
Transient ischaemic attack17.08.04.001; 24.04.06.005--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria23.04.02.001; 10.01.06.001--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages